ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Expert consensus on the diagnosis and differential diagnosis of indolent B-cell lymphomas in China (2025)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indolent B-cell lymphoma (iBCL) represents a group of mature B-cell clonal proliferative disorders that frequently involve the peripheral blood and bone marrow. In light of the fifth edition of the World Health Organization (WHO) classification of haematolymphoid tumors published in 2022, some changes have been introduced in the classification and nomenclature of certain iBCL subtypes. Accordingly, in this consensus, the disease spectrum of iBCL was reclassified based on the 2022 WHO framework. Reflecting this update, the Chinese expert consensus on the diagnosis of B-cell chronic lymphoproliferative disorders has been formally renamed as expert consensus on the diagnosis and differential diagnosis of indolent B-cell lymphomas in China. This consensus has been revised by the Hematological Oncology Committee of China Anti-Cancer Association, Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association, and Chinese Working Group for indolent lymphoma, following extensive discussions among domestic experts in hematologic oncology and pathology, with the goal of aligning with current clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.